natgillin/translations-raw huggingface dataset:
As with other AEDs, abrupt withdrawal of Lamictal may provoke rebound seizures. 
Kot velja za druge antiepileptike, lahko nenadna prekinitev Lamictala povzroči obratni odziv ("rebound") konvulzij.
The use of an ethinyloestradiol/levonorgestrel (30 µg/150 µg) combination increases the clearance of lamotrigine by approximately two-fold, resulting in decreased lamotrigine levels. 
Uporaba kombinacije etinilestradiol/levonorgestrel (30 µg/150 µg) za približno dvakrat poveča očistek lamotrigina in tako zmanjša koncentracijo lamotrigina.
PVC/PVdC/aluminium foil blister. 
Pretisni omot iz PVC/PVdC/aluminijske folije.
Lamotrigine has a slight inhibitory effect on dihydrofolic acid reductase, hence there is a possibility of interference with folate metabolism during long-term therapy (see section 4.6). 
Lamotrigin rahlo zavira dihidrofolat-reduktazo, zato med dolgotrajnim zdravljenjem obstaja možnost ovirane presnove folata (glejte poglavje 4.6).
The undesirable effects have been divided into epilepsy and bipolar specific sections based on the data currently available. 
Glede na podatke, ki so trenutno na voljo, so neželeni učinki razdeljeni na specifični poglavji pri epilepsiji in bipolarni motnji.
Therefore, consideration should be given to using contraception without a pill-free week, as first-line therapy (for example, continuous hormonal contraceptives or non-hormonal methods). 
Zato morajo imeti prednost pri izbiri kontracepcije takšna zdravila, ki ne vključujejo tedna brez tablet (npr. stalni hormonski kontraceptivi ali nehormonske metode).
conjunctivitis. 
konjunktivitis.
“After epileptic control has been achieved during adjunctive therapy, concomitant antiepileptic drugs (AEDs) may be withdrawn and patients continued on {Tradename} monotherapy”. 
„Po doseženem nadzoru epilepsije med dopolnilnim zdravljenjem je mogoče prenehati s sočasno uporabo drugih antiepileptičnih zdravil (AED), zdravljenje bolnikov pa se nadaljuje kot monoterapija z zdravilom {trgovsko ime zdravila}“.
- The scope of the referral was the harmonisation of the Summaries of Products Characteristics, labelling and package leaflet. 
- namen napotitve je bila uskladitev povzetkov glavnih značilnosti zdravila, označevanja in navodila za uporabo;
The other ingredients are: lactose monohydrate, microcrystalline cellulose, povidone K30, sodium starch glycolate (Type A), iron oxide yellow (E172) and magnesium stearate. 
Pomožne snovi so: laktoza monohidrat, mikrokristalna celuloza, povidon K30, natrijev karboksimetilškrob (tip A), rumeni železov oksid (E172) in magnezijev stearat.
PHARMACEUTICAL FORM AND CONTENTS 30 dispersible/chewable tablets 
FARMACEVTSKA OBLIKA IN VSEBINA 30 disperzibilnih/žvečljivih tablet
A total of 256 subjects between 1 to 24 months of age have been exposed to lamotrigine in the dose range 1 to 15 mg/kg/day for up to 72 weeks. 
Lamotriginu v odmerkih od 1 do 15 mg/kg/dan je bilo do 72 tednov izpostavljenih skupaj 256 preiskovancev, starih od 1 do 24 mesecev.
In reproductive and developmental toxicity studies in rodents and rabbits, no teratogenic effects but reduced foetal weight and retarded skeletal ossification were observed, at exposure levels below or similar to the expected clinical exposure. 
Raziskave reproduktivne in razvojne toksičnosti lamotrigina pri glodalcih in kuncih z odmerki, ki so bili nižji ali podobni pričakovani klinični izpostavitvi zdravilu, niso pokazale teratogenih učinkov, opazili pa so zmanjšanjo telesno težo zarodka in zapoznelo osifikacijo okostja .
Therefore in patients receiving concomitant therapy with oxcarbazepine, the treatment regimen for lamotrigine adjunctive therapy without valproate and without inducers of lamotrigine glucuronidation should be used (see section 4.2). 
Zato je treba pri bolnikih, ki sočasno dobivajo okskarbazepin, uporabiti režim zdravljenja za dodatno zdravljenje z lamotriginom brez valproata in brez induktorjev glukuronidacije lamotrigina (glejte poglavje 4.2).
In women not already taking an inducer of lamotrigine glucuronidation and taking a hormonal contraceptive that includes one week of inactive treatment (for example "pill-free week"), gradual transient increases in lamotrigine levels will occur during the week of inactive treatment (see section 4.2). 
Pri ženskah, ki ne prejemajo induktorja glukuronidacije lamotrigina in ki sočasno uporabljajo hormonske kontraceptive, se v tednu neaktivnega zdravljenja (npr. "teden brez tablete") koncentracija lamotrigina postopoma prehodno poveča (glejte poglavje 4.2).
Non-clinical data reveal no special hazard for humans based on studies of safety pharmacology, repeated dose toxicity, genotoxicity and carcinogenic potential. 
Predklinični podatki na osnovi raziskav farmakološke varnosti, toksičnosti pri ponavljajočih se odmerkih, genotoksičnosti in kancerogenega potenciala ne kažejo posebnega tveganja za človeka.
Measurement of serum lamotrigine concentrations before and after starting hormonal contraceptives may be considered, as confirmation that the baseline concentration of lamotrigine is being maintained. 
Priporočljivo je merjenje koncentracije lamotrigina v serumu pred začetkom uporabe hormonskih kontraceptivov in potem; tako se lahko prepričate, da se je vzdrževana koncentracija lamotrigina ohranila.
kidneys or blood, and may tell you to stop taking Lamictal. 
Zdravnik bo morda naročil preiskave jeter, ledvic ali krvi, ali vam bo naročil, da nehate jemati Lamictal.
• double vision or blurred vision 
• dvojen vid ali zamegljen vid
If epileptic control is achieved with adjunctive treatment, concomitant AEDs may be withdrawn and patients continued on Lamictal monotherapy. 
Če je epilepsija z dodatnim zdravljenjem nadzorovana, lahko sočasno uporabo antiepileptikov ukinete in nadaljujete monoterapijo z Lamictalom.
• in people who already have Parkinson's disease, worsening of the symptoms. 
• poslabšanje simptomov pri bolnikih, ki imajo Parkinsonovo bolezen
A decrease in lamotrigine levels has been associated with loss of seizure control. 
Zmanjšana koncentracijo lamotrigina je bila povezana z izgubo nadzora nad epileptičnimi napadi.
The syndrome shows a wide spectrum of clinical severity and may, rarely, lead to disseminated intravascular coagulation and multiorgan failure. 
Sindrom se lahko kaže v širšem obsegu, je klinično resen, v redkih primerih lahko povzroči diseminirano intravaskularno koagulacijo in odpoved različnih organov.
No adjustments to the recommended dose escalation guidelines for lamotrigine should be necessary solely based on the use of hormonal contraceptives, but the maintenance dose of lamotrigine will need to be increased or decreased in most cases when starting or stopping hormonal contraceptives (see section 4.2). 
Uporaba hormonskih kontraceptivov sama po sebi ne zahteva prilagoditve priporočenih smernic za zviševanje odmerka lamotrigina, večinoma pa je po začetku ali prenehanju jemanja hormonskih kontraceptivov treba zvišati ali znižati vzdrževalni odmerek lamotrigina (glejte poglavje 4.2).
nystagmus, tremor, insomnia. 
nistagmus, tremor, nespečnost.
Starter pack of 21 or 42 tablets. 
Začetno pakiranje z 21 ali 42 tabletami.
Apart from the indication in bipolar disorder the SPC of Lamictal in the different EU members show a large overlap. 
Razen indikacije za bipolarno motnjo so si povzetki glavnih značilnosti za zdravilo Lamictal v različnih državah članicah EU zelo podobni.
• valproate, used to treat epilepsy and mental health problems 
• valproat, ki se uporablja za zdravljenje epilepsije in težav z duševnim zdravjem,
There have been reports of adverse skin reactions, which have generally occurred within the first eight weeks after initiation of lamotrigine treatment. 
Na splošno so se pojavili v prvih osmih tednih po začetku zdravljenja z lamotriginom.
Specialist advice should be given to women who are of childbearing potential. 
Ženske v rodni dobi potrebujejo nasvet specialista.
5 mg dispersible/chewable tablets - where 2 mg dispersible/chewable tablets are not marketed and 5 mg dispersible/chewable tablets are the lowest marketed strength: <It should be noted that with the currently available Lamictal 5 mg dispersible/chewable tablet strength, it is not possible to accurately initiate lamotrigine therapy using the recommended dosing guidelines in paediatric patients weighing less than 17 kg.> 
5 mg disperzibilne/žvečljive tablete - kjer 2 mg disperzibilnih/žvečljivih tablet ni na trgu in so 5-mg disperzibilne/žvečljive tablete najmanjša jakost na trgu: <S trenutno dostopno jakostjo, Lamictal 5 mg disperzibilnimi/žvečljivimi tabletami ni mogoče začeti natančnega zdravljenja z lamotriginom, kot narekujejo smernice za odmerjanje pri pediatričnih bolnikih, lažjih od 17 kg.>
2 4 6 8 10 12 14 (no pocket) 
2 4 6 8 10 12 14 (brez žepka)
If you take more Lamictal than you should 
Če ste vzeli večji odmerek zdravila Lamictal, kot bi smeli:
Mean half-life is reduced to approximately 14 hours when given with glucuronidation-inducing medicinal products such as carbamazepine and phenytoin and is increased to a mean of approximately 70 hours when co-administered with valproate alone (see section 4.2). 
Povprečni razpolovni čas se skrajša na približno 14 ur, če je lamotrigin uporabljen sočasno z zdravili, ki inducirajo glukuronidacijo, npr. s karbamazepinom ali fenitoinom, in se podaljša povprečno za približno 70 ur, če je uporabljen sočasno z valproatom (glejte poglavje 4.2).
This dosage regimen should be used when the following are added without valproate: 
Ta režim odmerjanja morate uporabiti, kadar dodate katerega od naslednjih zdravil brez uporabe valproata:
• carbamazepine, used to treat epilepsy and mental health problems 
• karbamazepin, ki se uporablja za zdravljenje epilepsije in težav z duševnim zdravjem,
In patients receiving concomitant therapy with phenytoin, carbamazepine, pheonbarbitone or primidone, the appropriate treatment regimen should be used (see section 4.2). 
Za bolnike, ki se sočasno zdravijo s fenitoinom, karbamazepinom, fenobarbitonom ali primidonom, morate uporabiti ustrezen režim zdravljenja (glejte poglavje 4.2).
Each dispersible/chewable tablet contains 2 mg, 5 mg, 25 mg, 50 mg, 100 mg or 200 mg lamotrigine. 
Ena disperzibilna/žvečljiva tableta vsebuje 2 mg, 5 mg, 25 mg, 50 mg, 100 mg ali 200 mg lamotrigina.
- Monotherapy of typical absence seizures. 
- Monoterapija pri tipičnih napadih odsotnosti.
2 mg dispersible/chewable tablets - where this is the lowest marketed strength: <* If the calculated daily dose in patients taking valproate is 1 mg or more but less than 2 mg, then Lamictal 2 mg dispersible/chewable tablets may be taken on alternate days for the first two weeks. 
2 mg disperzibilne/žvečljive tablete - kjer je to najmanjša jakost na trgu: <* Če je izračunani dnevni odmerek za bolnike, ki jemljejo valproat, 1 mg ali več, toda manj kot 2 mg, lahko bolnik prva dva tedna dobiva Lamictal 2 mg disperzibilne/žvečljive tablete vsak drugi dan.
8 9 10 11 12 13 14 (1 pocket) 
8 9 10 11 12 13 14 (1 žepek)
The seizures in some types of epilepsy may occasionally become worse or happen more often while you're taking Lamictal. 
Občasno se lahko med jemanjem zdravila Lamictal napadi krčev pri nekaterih vrstah epilepsije poslabšajo ali postanejo pogostejši.
During the pill-free week, a two-fold increase in lamotrigine levels has been observed. 
V tednu brez hormonskih tablet so opazili dvakrat višjo koncentracijo lamotrigina.
Free of mania p-value Log rank test 
Brez manije p vrednost (log-rank test)
Allergic reaction or potentially serious skin reaction: get a doctor's help straight away A small number of people taking Lamictal get an allergic reaction or potentially serious skin reaction, which may develop into more serious, and even life-threatening, problems if they are not treated. 
Maloštevilnim bolnikom se lahko med jemanjem zdravila Lamictal pojavi alergijska reakcija ali potencialno resna kožna reakcija, ki se lahko razvije v še resnejšo in celo smrtno nevarno, če ni zdravljena.
Glaxo Group Ltd Berkeley Avenue Greenford Middlesex UB6 0NN United Kingdom 
Glaxo Group Ltd Berkeley Avenue Greenford Middlesex UB6 0NN Velika Britanija
10 dispersible/chewable tablets 14 dispersible/chewable tablets 28 dispersible/chewable tablets 30 dispersible/chewable tablets 50 dispersible/chewable tablets 56 dispersible/chewable tablets 
10 disperzibilnih/žvečljivih tablet 14 disperzibilnih/žvečljivih tablet 28 disperzibilnih/žvečljivih tablet 30 disperzibilnih/žvečljivih tablet 50 disperzibilnih/žvečljivih tablet 56 disperzibilnih/žvečljivih tablet
• clumsiness and lack of co-ordination (ataxia) 
• okornost in pomanjkljiva usklajenost gibov (ataksija)
Effect of hormonal contraceptives on lamotrigine pharmacokinetics In a study of 16 female volunteers, dosing with 30 µg ethinyloestradiol/150 µg levonorgestrel in a combined oral contraceptive pill caused an approximately two-fold increase in lamotrigine oral clearance, resulting in an average 52% and 39% reduction in lamotrigine AUC and Cmax, respectively. 
Vpliv hormonskih kontraceptivov na farmakokinetiko lamotrigina V študiji 16 prostovoljk je uporaba kombiniranih kontracepcijskih tablet s 30 µg etinilestradiola/150 µg levonorgestrela povzročila približno dvakratno povečanje očistka peroralnega lamotrigina, to pa je povzročilo povprečno 52 % zmanjšanje AUC in povprečno 39 % zmanjšanje Cmax lamotrigina.
10 dispersible/chewable tablets 30 dispersible/chewable tablets 50 dispersible/chewable tablets 56 dispersible/chewable tablets 60 dispersible/chewable tablets 90 dispersible/chewable tablets 100 dispersible/chewable tablets 200 dispersible/chewable tablets 
10 disperzibilnih/žvečljivih tablet 30 disperzibilnih/žvečljivih tablet 50 disperzibilnih/žvečljivih tablet 56 disperzibilnih/žvečljivih tablet 60 disperzibilnih/žvečljivih tablet 90 disperzibilnih/žvečljivih tablet 100 disperzibilnih/žvečljivih tablet 200 disperzibilnih/žvečljivih tablet
42 tablets 
42 tablet
Lamictal should not be administered to patients currently being treated with any other preparation containing lamotrigine without consulting a doctor. 
Bolniki, ki jemljejo druga zdravila, ki vsebujejo lamotrigin, zdravila Lamictal ne smejo prejeti brez posveta z zdravnikom.
Starter pack of 42 tablets. 
Začetno pakiranje z 42 tabletami.
• Swallow your tablets whole. 
• Tablete pogoltnite cele.
Each tablet contains 25 mg, 50 mg, 100 mg or 200 mg lamotrigine. 
Ena tableta vsebuje 25 mg, 50 mg, 100 mg ali 200 mg lamotrigina.
Medicinal products that significantly induce glucuronidation of lamotrigine 
Zdravila, ki pomembno inducirajo glukuronidacijo lamotrigina
The other ingredients are: calcium carbonate, low substituted hydroxypropyl cellulose, aluminium magnesium silicate, sodium starch glycolate (Type A), povidone K30, saccharin sodium, magnesium stearate, blackcurrant flavour. 
Pomožne snovi so: kalcijev karbonat, delno substituirana hidroksipropilceluloza, aluminijev magnezijev silikat, natrijev karboksimetilškrob (tip A), povidon K30, natrijev saharinat, magnezijev stearat, okus črnega ribeza.
Depression free p-value Log rank test 
Brez depresije p vrednost (log-rank test)
Effects of hormonal contraceptives on lamotrigine efficacy The use of an ethinyloestradiol/levonorgestrel (30 µg/150 µg) combination increases the clearance of lamotrigine by approximately two-fold resulting in decreased lamotrigine levels (see section 4.5). 
Vpliv hormonskih kontraceptivov na učinkovitost lamotrigina Uporaba kombinacije etinilestradiol/levonorgestrel (30 µg/150 µg) za približno dvakrat poveča očistek lamotrigina in tako zmanjša koncentracijo lamotrigina (glejte poglavje 4.5).
**Rash has also been reported as part of a hypersensitivity syndrome associated with a variable pattern of systemic symptoms including fever, lymphadenopathy, facial oedema and abnormalities of the blood and liver. 
**O izpuščaju so poročali tudi kot o delu preobčutljivostnega sindroma, ki ga spremljajo različne kombinacije sistemskih simptomov, vključno z zvišano telesno temperaturo, limfadenopatijo, edemom obraza in nepravilnostmi krvi in jeter.
In women who wish to stop taking a hormonal contraceptive that includes one week of inactive treatment ("pill-free week"), serum lamotrigine level monitoring should be conducted during week 3 of active treatment, i.e. on days 15 to 21 of the pill cycle. 
Če ženska želi prenehati uporabljati hormonski kontraceptiv, ki vključuje teden brez učinkovin ("teden brez tablet"), je treba koncentracijo lamotrigina v serumu kontrolirati v 3. tednu uporabe učinkovin, tj. od 15. do 21. dneva ciklusa kontracepcijskih tablet.
The undesirable effects below should be considered alongside those seen in epilepsy for an overall safety profile of lamotrigine. 
Za celotno oceno varnosti lamotrigina morate poleg spodaj naštetih neželenih učinkov upoštevati tudi tiste, ki se pojavljajo pri epilepsiji.
tiredness. 
driska.
In women taking a hormonal contraceptive that includes one week of inactive treatment ("pill-free week"), serum lamotrigine level monitoring should be conducted during week 3 of active treatment, i.e. on days 15 to 21 of the pill cycle. 
Če ženska uporablja hormonski kontraceptiv, ki vključuje teden brez učinkovin ("teden brez tablet"), je treba koncentracijo lamotrigina v serumu kontrolirati v 3. tednu uporabe učinkovin, tj. od 15. do 21. dneva ciklusa kontracepcijskih tablet.
nausea, vomiting. 
navzeja, bruhanje.
Lamictal can cause dizziness and double vision. 
Vpliv na sposobnost upravljanja vozil in strojev Lamictal lahko povzroči omotico in dvojen vid.
For patients with end-stage renal failure, initial doses of lamotrigine should be based on patients' concomitant medicinal products; reduced maintenance doses may be effective for patients with significant renal functional impairment (see sections 4.4 and 5.2). 
Pri bolnikih z ledvično odpovedjo v zadnji fazi morajo začetni odmerki lamotrigina temeljiti na sočasni uporabi drugih zdravil; pri bolnikih s pomembno okvarjenim delovanjem ledvic pa so lahko učinkoviti že nižji vzdrževalni odmerki (glejte poglavji 4.4 in 5.2).
150 mg/day Maintain this dose (150 mg/day) 
150 mg/dan Vzdržujte ta odmerek (150 mg/dan)
Because of the risk of rash the initial dose and subsequent dose escalation should not be exceeded (see section 4.4). 
Zaradi tveganja za pojav izpuščaja začetnega odmerka in kasnejšega zviševanja odmerka ne smete prekoračiti (glejte poglavje 4.4).
Rash has also been reported as part of a hypersensitivity syndrome associated with a variable pattern of systemic symptoms including fever, lymphadenopathy, facial oedema and abnormalities of the blood and liver (see section 4.8). 
Izpuščaj je opisan tudi kot del preobčutljivostnega sindroma, ki ga spremlja različni sistemski simptomi, vključno z zvišano telesno temperaturo, limfadenopatijo, edemom obraza in nepravilnostmi krvi in jeter (glejte poglavje 4.8).
Maintain target dose achieved in dose escalation (200 mg/day; dose range 100-400 mg/day) 
Vzdržujte ciljni odmerek, dosežen pri zviševanju odmerka (200 mg/dan; razpon odmerkov od 100 do 400 mg/dan)
200 mg/day Maintain this dose (200 mg/day) (two divided doses) 
200 mg/dan Vzdržujte ta odmerek (200 mg/dan) (v dveh deljenih odmerkih)
somnolence, dizziness, tremor, insomnia. 
zaspanost, omotica, tremor, nespečnost.
15 16 17 18 19 20 21 (2 pockets) 
15 16 17 18 19 20 21 (2 žepka)
arthralgia. 
artralgija.
When concomitant AEDs are withdrawn or other AEDs/medicinal products are added on to treatment regimes containing lamotrigine, consideration should be given to the effect this may have on lamotrigine pharmacokinetics (see section 4.5). 
Če pri zdravljenju z lamotriginom prenehate s sočasno uporabljenimi antiepileptiki, ali v zdravljenje vključite druge antiepileptike oz. druga zdravila, morate upoštevati možni vpliv le-tega na farmakokinetiko lamotrigina (glejte poglavje 4.5).
“Adults 18 years and above {Tradename} is indicated for the prevention of mood episodes in patients with bipolar disorder, predominantly by preventing depressive episodes”. 
Zdravilo {trgovsko ime zdravila} je indicirano za preprečevanje nihanj razpoloženja pri bolnikih z bipolarno motnjo, predvsem za preprečevanje epizod depresije“.
The median apparent clearance of lamotrigine was 0.31, 0.24 or 0.10 mL/min/kg in patients with Grade A, B, or C (Child-Pugh Classification) hepatic impairment, respectively, compared with 0.34 mL/min/kg in the healthy controls. 
Srednji navidezni očistek lamotrigina je bil pri bolnikih z okvaro jeter stopnje A po Child-Pughu 0,31 ml/min/kg, stopnje B 0,24 ml/min/kg in stopnje C 0,10 ml/min/kg; pri zdravih kontrolnih osebah je bila ta vrednost 0,34 ml/min/kg.
0.15 mg/kg/day* (once a day) 
0,15 mg/kg/dan* (enkrat na dan)
200 mg/day - usual target dose for optimal response (once a day or two divided doses) 
200 mg/dan - običajni ciljni odmerek za optimalen odziv (enkrat na dan ali v dveh deljenih odmerkih)
12.5 mg/day (given as 25 mg on alternate days) 
12,5 mg/dan (kot 25 mg vsak drugi dan)
100 mg/day - usual target dose for optimal response (once a day or two divided doses) 
100 mg/dan - običajni ciljni odmerek za optimalen odziv (enkrat na dan ali v dveh deljenih odmerkih)
16 18 20 22 24 26 28 (one pocket) 
16 18 20 22 24 26 28 (en žepek)
They are marked ‘GSEC5' on one side; and ‘200' on the other. 
Na eni strani imajo oznako ‘GSEC5', na drugi strani pa oznako ‘200'.
People with bipolar disorder can sometimes have thoughts of harming themselves or committing suicide. 
Razmišljanje o samopoškodovanju ali samomoru Pri bolnikih z bipolarno motnjo se občasno lahko pojavijo misli na samopoškodovanje ali samomor.
• in people who already have epilepsy, seizures happening more often 
• pogostejši epileptični napadi pri bolnikih, ki imajo epilepsijo
Variations in lamotrigine levels of this order may be associated with adverse effects. 
Takšne spremembe v koncentraciji lamotrigina lahko spremljajo neželeni učinki.
• risperidone, used to treat mental health problems 
• risperidon, ki se uporablja za zdravljenje težav z duševnim zdravjem,
0.3 mg/kg/day (once a day) 
0,3 mg/kg/dan (enkrat na dan)
Starter pack 21 tablets, valproate add-on therapy Starter pack 42 tablets, monotherapy 
Začetno pakiranje z 21 tabletami, dodatek zdravljenja z valproatom Začetno pakiranje z 42 tabletami, monoterapija
300 mg/day 400 mg/day Maintain this dose (400 mg/day) 
300 mg/dan 400 mg/dan Vzdržujte ta odmerek (400 mg/dan)
Lamotrigine reduced foetal folic acid levels in rats. 
Lamotrigin je pri podganah znižal koncentracijo folne kisline zarodka.
25, 50, 100 and 200 mg tablets: Excipient of Lamictal tablets 
25-, 50-, 100- in 200 mg tablete: Pomožna snov v tableti Lamictal
The recommended dose escalation and maintenance doses for adults of 18 years of age and above are given in the tables below. 
V spodnjih preglednicah je navedeno priporočeno zviševanje odmerka in vzdrževalni odmerki za odrasle od 18. leta starosti.
Usually treatment is started as monotherapy; then if the control of the symptoms is not reached, other medicines are added based on the experience of the physician. 
Če nadzor simptomov ni dosežen, zdravnik glede na svoje izkušnje doda druga zdravila.
Therapy aimed at decreasing absorption (activated charcoal, laxative or gastric lavage) should be performed if indicated. 
Če je indicirano, uporabite terapijo za zmanjšanje absorpcije (aktivno oglje, odvajalo ali izpiranje želodca).
Efficacy as monotherapy treatment of typical absence seizures was demonstrated. 
Dokazana je bila učinkovitost monoterapije pri tipičnih napadih odsotnosti.
Increases in lamotrigine concentrations may be associated with dose-related adverse events. 
Povečanje koncentracije lamotrigina lahko spremljajo od odmerka odvisni neželeni učinki.
Clearance adjusted for body weight is higher in children than in adults with the highest values in children under five years. 
Vrednosti očistka so največje pri otrocih, mlajših od pet let.
However, the possibility of these changes resulting in decreased contraceptive efficacy in some patients taking hormonal preparations with lamotrigine cannot be excluded. 
Vpliv teh sprememb na ovulacijsko aktivnost jajčnikov ni znan, vendar pri nekaterih bolnicah ni mogoče izključiti zmanjšane učinkovitosti kontraceptiva , ki so sočasno prejemale hormonske pripravke in lamotrigin.
22 23 24 25 26 27 28 (2 pockets) 
22 23 24 25 26 27 28 (2 žepka)